10-Q: RenovoRx Reports Q2 Revenue Growth, Advances Pancreatic Cancer Trial

RenovoRx, Inc. announced significant revenue growth from RenovoCath sales and positive progress in its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.

Summary

• Revenue from RenovoCath sales reached $422,000 for the three months ended June 30, 2025, a substantial increase from zero in the prior year period, and $619,000 for the six months ended June 30, 2025.
• Net loss for the three months ended June 30, 2025, was $(2,895,000), compared to $(2,389,000) for the same period in 2024, primarily due to a negative change in the fair value of common warrant liability.
• Net loss for the six months ended June 30, 2025, was $(5,315,000), compared to $(3,465,000) for the same period in 2024.
• The company's cash and cash equivalents increased to $12,314,000 as of June 30, 2025, from $7,154,000 at December 31, 2024, largely due to a $10,845,000 net cash provided by financing activities.
• The accumulated deficit grew to $(55,534,000) as of June 30, 2025.
• The independent Data Monitoring Committee (DMC) for the Phase III TIGeR-PaC trial recommended continuing the trial after its second interim analysis, triggered by the 52nd event.
• As of August 12, 2025, 95 patients have been randomized and 61 events have occurred in the TIGeR-PaC trial, with enrollment on target to complete this year or early next year.
• A new multi-center post-marketing registry study, PanTheR (NCT06805461), was launched in July 2025 to evaluate RenovoCath for targeted chemotherapy delivery in solid tumors.
• Material weaknesses in internal control over financial reporting, previously identified, have not yet been remediated, but the company is implementing measures to address them.

Sentiment

Score: 6

Explanation: The company shows promising commercial traction with RenovoCath and positive clinical trial progress for TIGeR-PaC, including a DMC recommendation to continue. However, it continues to incur significant net losses and negative cash flows, and has un-remediated material weaknesses in internal controls, indicating ongoing financial and operational challenges. The need for future capital raises and potential dilution are also significant considerations.

Positives

• Generated $422,000 in revenue from RenovoCath sales for the three months ended June 30, 2025, a significant increase from no revenue in the prior year, indicating successful early commercialization efforts.
• Q2 2025 RenovoCath sales revenue of $420,000 represents a substantial increase from $197,000 in Q1 2025, demonstrating growing market traction and repeat customer orders.
• The independent Data Monitoring Committee (DMC) recommended continuing the pivotal Phase III TIGeR-PaC trial after its second interim analysis, which is an expression of confidence in the potential for a positive outcome.
• Launched the multi-center post-marketing registry study, PanTheR, in July 2025, which will further evaluate RenovoCath's safety and effectiveness in real-world settings and inform future clinical trial designs.
• Secured $10,845,000 in net cash from financing activities for the six months ended June 30, 2025, significantly bolstering cash reserves to $12,314,000.
• Maintains a robust intellectual property portfolio with 19 issued patents and 12 pending patents covering its TAMP technology.
• Net loss per share improved to $(0.08) for the three months ended June 30, 2025, from $(0.10) in the prior year, despite a higher net loss, due to increased share count.

Negatives

• Incurred a net loss of $(2,895,000) for the three months ended June 30, 2025, an increase of 21% compared to $(2,389,000) in the prior year period.
• Reported a net loss of $(5,315,000) for the six months ended June 30, 2025, a 53% increase from $(3,465,000) in the prior year period.
• Accumulated deficit increased to approximately $(55,534,000) as of June 30, 2025, indicating continued historical losses.
• Net cash used in operating activities increased to $(5,683,000) for the six months ended June 30, 2025, from $(4,501,000) in the prior year, reflecting an increased cash burn.
• Experienced a significant negative swing of $(857,000) in the change in fair value of common warrant liability for the three months ended June 30, 2025, compared to a gain in the prior year.
• Material weaknesses in internal control over financial reporting, related to the control environment and lack of appropriate GAAP technical expertise for complex transactions, have not been remediated.
• The company expects to continue incurring significant losses and negative cash flows from operations until RenovoCath commercialization generates sufficient revenues or IAG receives regulatory approval.

Risks

• No drug/device combination products are approved for commercial sale, and the company has limited experience in commercializing standalone medical devices, making future success difficult to predict.
• Continued significant net losses are expected until FDA approval for product candidates or sufficient revenue from RenovoCath sales.
• The commercial strategy for RenovoCath as a standalone device is new and subject to significant inherent risks, and revenue growth may not meet expectations.
• Estimates of total addressable market, potential revenues, and clinical trial completion/data readout timing may prove inaccurate.
• Revenue recognition from RenovoCath commercialization activities could be complex and uncertain, potentially requiring deferral.
• Revenues and results of operations may be difficult to predict and could fluctuate significantly from quarter to quarter.
• Reliance on third-party manufacturers, such as Medical Murray, for RenovoCath production poses risks of delays or non-compliance with regulations.
• Substantial additional capital will likely be needed to develop and commercialize IAG and expand RenovoCath sales; failure to obtain funding could force delays, reductions, or termination of programs, and impact the company's ability to continue as a going concern.
• Strategic alternatives (financing, alliances, licensing) may be considered but may not be identified or consummated successfully.
• Commercial viability of product candidates depends on successful preclinical studies, clinical trials (notably Phase III TIGeR-PaC), and regulatory approvals, which are not guaranteed.
• Failure of the Phase III TIGeR-PaC trial to achieve positive results could significantly harm the company.
• Failure to achieve projected development goals in announced timeframes could lead to a decline in stock price.
• Product candidates may exhibit undesirable side effects, delaying or precluding further development or regulatory approval.
• Negative results from preclinical studies or clinical trials could materially harm the business.
• Inability to satisfy regulatory requirements could prevent commercialization of product candidates.
• Competition from existing or future marketed drugs could reduce or eliminate commercial opportunities.
• Development of product candidates may be delayed or terminated if the perceived market opportunity does not justify further investment.
• Future success depends on retaining key personnel and attracting qualified talent, especially in a competitive compensation environment.
• Inability to effectively protect intellectual property could impair competitive advantage.
• Issued patents may not provide meaningful protection, or competitors may design around proprietary technologies.
• The market price of common stock may be volatile and fluctuate substantially.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting, harming stock liquidity and capital raising ability.

Future Outlook

The company expects to continue incurring significant expenses, operating losses, and negative cash flows as it grows RenovoCath commercial sales and completes development and regulatory approval for IAG. Expenses are anticipated to increase with further clinical development, expansion of commercial sales efforts, hiring of additional personnel, pursuit of collaborations, intellectual property protection, and expansion of operational systems. The company believes its current cash and cash equivalents will fund operations for at least the next 12 months, assuming commercial strategy and development programs advance as contemplated. However, additional capital will likely be required, which may be sought through equity/debt financings or collaborations, with no assurance of favorable terms or availability.

Management Comments

• We are encouraged by the strong demand we are experiencing with RenovoCath and the resulting growth in RenovoCath sales revenue we have experienced to date.
• We have seen meaningful traction across a diverse group of medical institutions, including several high-volume, academic, and National Cancer Institute-designated centers, which we believe speaks to the growing confidence in our technology by our customers.
• Our goal is to significantly increase the revenue over time.
• We believe the independent DMC's recommendation is an expression of confidence in the potential for a positive outcome in the trial overall.
• With a view towards preserving the integrity of the TIGeR-PaC trial for FDA purposes, and following our review of general FDA guidance, discussions with the independent DMC, and consultation with our regulatory advisors, we have decided to defer publishing the detailed data from the second interim analysis.
• We anticipate that this momentum may translate into additional commercial opportunities following the completion of TIGeR-PaC trial enrollment.
• Based on our internal assumptions, we believe that our initial total U.S. addressable market based solely on the initial clinical interest we have received for RenovoCath could represent an estimated $400 million peak annual U.S. sales opportunity.
• This serves as the basis for our belief in the potential for a several-billion-dollar TAM as we expand into additional cancer indications.
• Based on our operating plans, we expect that our current cash and cash equivalents as of the date of this Report will be sufficient to fund our operating, investing and financing cash flow needs through at least the next 12 months, assuming our commercial strategy and our development programs advance as currently contemplated.

Industry Context

RenovoRx operates in the highly competitive and rapidly evolving life sciences sector, specifically targeting difficult-to-treat cancers with its novel drug-device combination product, IAG, and its standalone RenovoCath device. The launch of the PanTheR post-marketing registry study aligns with broader industry trends of collecting real-world data to demonstrate long-term safety and effectiveness, which is crucial for market adoption and informing future clinical development. The focus on targeted therapeutic delivery, aiming to minimize systemic toxicities, addresses a significant unmet need in oncology, particularly for challenging indications like pancreatic cancer. The company's commercialization of RenovoCath as a standalone device taps into the growing demand for specialized medical devices in interventional oncology, while its Phase III trial for IAG positions it for potential entry into the drug-device combination market, a segment with high regulatory hurdles but also high potential rewards.

Comparison to Industry Standards

• The company's commercialization efforts for RenovoCath are in early stages, making direct comparisons to established industry leaders challenging. However, the reported revenue growth from zero to $422,000 in Q2 2025, driven by new and repeat orders from high-volume cancer centers, suggests positive initial market acceptance for a novel device.
• The independent Data Monitoring Committee's recommendation to continue the Phase III TIGeR-PaC trial is a positive signal, aligning with standard clinical trial progression for pivotal studies. Deferring detailed interim data publication to preserve trial integrity is a common practice in late-stage clinical development, similar to how larger pharmaceutical companies manage sensitive trial information.
• The estimated $400 million peak annual U.S. sales opportunity for RenovoCath, with a potential for a several-billion-dollar Total Addressable Market (TAM) by expanding into additional cancer indications, positions the company in a high-growth segment of the oncology device market, comparable to the market potential seen by other innovative medical device companies in specialized fields.
• The company's accumulated deficit of $55.5 million and ongoing net losses are typical for clinical-stage life science companies heavily investing in R&D and early commercialization, similar to many biotech and medtech startups prior to significant product approvals or widespread market penetration.

Corporate Governance

Legal Proceedings

• The company was not subject to any material legal proceedings during the three and six months ended June 30, 2025, and no material legal proceedings are subsequently outstanding or pending.

Related Party Transactions

• Consulting fees of $84,000 were paid to Dr. Ramtin Agah (co-founder and Chief Medical Officer) for the three months ended June 30, 2025, and $168,000 for the six months ended June 30, 2025.
• A discretionary bonus of $121,000 was paid to Dr. Agah in February 2025 in recognition of company and individual performance achieved in 2024.

Stakeholder Impact

• **Shareholders**: Experience dilution from recent equity financings and potential future capital raises. The stock price may be volatile due to ongoing losses and the speculative nature of clinical-stage development, balanced by positive commercialization and trial progress.
• **Employees**: Benefit from stock-based compensation plans and potential for increased hiring in sales and marketing roles. Key personnel retention is critical for the company's success.
• **Customers (Medical Institutions)**: Benefit from the availability of RenovoCath for standalone use and participation in the PanTheR registry study, indicating growing confidence in the technology.
• **Suppliers (Medical Murray, Inc.)**: Have a commercial supply agreement with minimum order quantities, ensuring a continued business relationship.
• **Regulatory Authorities**: The company is subject to SEC reporting requirements and FDA regulations for its medical devices and drug-device combination products, with ongoing compliance efforts.

Next Steps

• Continue to enroll patients in the ongoing Phase III TIGeR-PaC clinical trial, with enrollment targeted for completion this year or early next year.
• Advance clinical development of IAG and the TAMP platform technology, including exploring other preclinical and clinical pipeline indication opportunities beyond LAPC.
• Expand and launch the PanTheR multi-center post-marketing registry study to evaluate RenovoCath for chemotherapy delivery to solid tumors.
• Make targeted investments to expand RenovoCath commercial sales efforts, including hiring a small number of RenovoCath salespeople in the second half of 2025.
• Gather important market data (sales cycles, activation times, customer preferences) to grow the customer base and fulfill repeat RenovoCath orders.
• Evaluate potential collaborations with larger organizations to accelerate RenovoCath sales efforts.
• Implement measures to remediate identified material weaknesses in internal control over financial reporting, including engaging additional accounting and financial reporting personnel, developing an accounting policy manual, and establishing effective monitoring and oversight controls.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.

Key Dates

Recommendation

RenovoRx presents a mixed financial picture. While the company has demonstrated promising initial commercial traction with its RenovoCath device, generating revenue growth, and received a positive recommendation from the DMC for its pivotal TIGeR-PaC trial, it continues to incur significant net losses and negative cash flows. The identified material weaknesses in internal controls also pose a concern. The recent capital raise provides near-term liquidity, but the company explicitly states the need for substantial additional capital in the future, which could lead to further shareholder dilution. Given the early stage of commercialization, the inherent risks of clinical trials, and the ongoing financial challenges, a 'hold' recommendation is appropriate. Investors should monitor the progress of RenovoCath sales, the TIGeR-PaC trial results, and the remediation of internal control weaknesses before making further investment decisions.

Keywords

RenovoRx, RenovoCath, TIGeR-PaC, PanTheR, Pancreatic Cancer, Locally Advanced Pancreatic Cancer, LAPC, Targeted Chemotherapy Delivery, Drug-Device Combination, Medical Device, Oncology, Life Sciences, Clinical Stage, Commercial Stage, FDA Cleared, Phase III Clinical Trial, Post-Marketing Registry Study, TAMP Therapy Platform, Orphan Drug Designation, SEC Filing, 10-Q, Financial Results